Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.

Wuqiang Lin,Xiuli Chen,Heyong Zheng,Zhenjie Cai

Hematology (Amsterdam, Netherlands)（2023）

引用 0|浏览1

暂无评分

摘要

CDC37 decreases after bortezomib-based induction treatment, while its higher expression reflects unsatisfactory induction treatment response and survival in multiple myeloma.

查看译文

关键词

multiple myeloma patients,multiple myeloma,cell division,bortezomib-based

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要